Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 597Stomach Neoplasms 72Neoplasm Metastasis 56Neoplasms 35HER2-positive Breast Cancer 30Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Pathologic Complete Response 6

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Trastuzumab × Clear all
NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

SCRI Development Innovations, LLC

Phase 2 Completed
127 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡